MedTrace Logo

A Study of an Investigational Zoster Vaccine, in Subjects With a History of Herpes Zoster (V211-014)

NCT00322231 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 101

Last updated 2015-01-26

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether the investigational zoster vaccine, is generally well tolerated when administered to participants with a history of herpes zoster.

Conditions

  • Herpes Zoster

Interventions

BIOLOGICAL

zoster vaccine live (ZOSTAVAX™)

1 dose 0.65 mL/dose subcutaneous injection of zoster vaccine live

BIOLOGICAL

Comparator: Placebo

1 dose 0.65 mL/dose subcutaneous injection of placebo.

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2007-07-31
Completion
2007-07-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00322231 on ClinicalTrials.gov